and the Pharmacy Compounding Advisory Committee subsequently voted against adding it to the Category 1/503A bulk drug substances list at its late-2024 meetings, leaving it without a confirmed legal compounding pathway at that time
Current clinical useparticularly within sports medicine and regenerative medicine practicesis largely based on case reports, anecdotal experience, and mechanistic rationale rather than large-scale randomized controlled trials
Red flags that require immediate care Some symptoms should never be ignored
gastric ulcers, duodenal ulcers, and mucosal erosion where direct local peptide delivery to the damaged tissue is the therapeutic goal Inflammatory bowel conditions: Crohn's disease and ulcerative colitis support, where VEGF-mediated mucosal angiogenesis and anti-inflammatory effects have been investigated Leaky gut and intestinal hyperpermeability: tight junction restoration and mucosal integrity support in patients with compromised gut barrier function Gastroparesis: pro-motility effects via vagal cholinergic pathways investigated in preclinical models of delayed gastric emptying
Cooperrider J, Furmaga H, Plow E, Park H-J, Chen Z, Kidd G, et al
318 (4), G717G724
